Hatteras Venture Partners has held the first closing of Hatteras Venture Partners VI, LP (HVP VI),says with USD94 million in deployable capital toward an ultimate target fund size of USD200 million.
“The pace and quality of our deal flow has grown tremendously during the past several years,” said Clay Thorp, Co-founder and General Partner of Hatteras. “With HVP VI, we will continue to partner with innovative, driven entrepreneurs to launch and build world-class health care companies, many of which will be based upon leading-edge research stemming from the renowned academic centres in the southeastern U.S. In addition, we will continue to leverage our expanding national network to co-invest in promising companies in other regions.”
To support the firm’s continued growth, coincident with the closing of the new fund, Hatteras announced the promotions of Mike Dial, PhD, and Jeff Terrell to Partner. Dr Dial and Terrell both joined Hatteras as analysts and have honed their respective skills as investors, board members and strategic thinkers while continuing to take on increasing responsibility.
“Mike and Jeff have proven themselves to be invaluable members of the Hatteras team,” says Robert A Ingram, General Partner of Hatteras. “They will be key drivers in our funds’ performance going forward.”
In addition to the promotions of Dial and MTerrell, Hatteras has added Ben Scruggs, PhD, as Associate, and Kseniya Simpson, PhD, as Analyst. Drs. Scruggs and Simpson earned their doctorate degrees from preeminent academic institutions Washington University in St Louis and Yale University, respectively. Both are core members of the investment team, which has capability to analyse and add value to a range of companies solving critical, unmet medical needs.
